| name | Strontium Ranelate |
| classification | Bisphosphonate-like drug; Antiresorptive agent used in the treatment of osteoporosis. |
| pharmacokinetics | | absorption | Poorly absorbed from the gastrointestinal tract. Absorption is increased by food and high gastric pH. | | distribution | Widely distributed in the body. Concentrates in bone. | | metabolism | Minimal metabolism in the liver and kidneys. | | excretion | Primarily excreted unchanged by the kidneys. This can cause accumulation in patients with renal impairment. |
|
| suggested dosage | The recommended dosage of strontium ranelate for osteoporosis treatment is 2 grams per day, taken as a single oral dose with a full glass of water before or after a meal. |
| indications | | 1 | Treatment of postmenopausal osteoporosis to reduce the risk of vertebral and hip fractures. May be considered for men in certain cases, but efficacy in this population is less well established than in postmenopausal women. | | 2 | Prevention of osteoporosis in high risk cases (depending on individual assessment) |
|
| safety in pregnancy | Contraindicated during pregnancy due to potential risks to the fetus and adverse effects in the mother. There are insufficient studies to provide a definitive answer to risk of congenital anomalies. |
| safety in breastfeeding | Not recommended during breastfeeding; it's unknown whether strontium ranelate is secreted in breast milk. |
| side effects | | 1 | Nausea, vomiting, diarrhea, constipation | | 2 | Headache, dizziness | | 3 | Arthralgia, myalgia, back pain | | 4 | Increased risk of cardiovascular events (such as deep vein thrombosis, pulmonary embolism, stroke) – this is a major concern and warrants careful consideration in the patient's overall risk profile. | | 5 | Skin rash, itching | | 6 | Increased risk of urinary tract infections | | 7 | Allergic reactions (rare) |
|
| alternatives | |
| contraindications | | 1 | Hypersensitivity to strontium ranelate | | 2 | Severe renal impairment | | 3 | History of cardiovascular events or significant risk factors (e.g., hypertension, hyperlipidemia, diabetes) | | 4 | Active or history of deep vein thrombosis or pulmonary embolism | | 5 | Patients with significant gastrointestinal disorders that can affect absorption. |
|
| interactions | | 1 | Concomitant use with other drugs that can affect renal function | | 2 | Interaction with other medications used to treat osteoporosis may exist, but the specific interactions need to be addressed by a doctor. |
|
| warnings and precautions | | 1 | Monitor renal function | | 2 | Closely monitor for cardiovascular events, especially in patients with existing risk factors | | 3 | Monitor for gastrointestinal side effects and advise on proper administration (with a full glass of water on an empty stomach) | | 4 | Careful assessment of the individual's risk profile and benefits/risks of the treatment is essential | | 5 | Patients should inform their physician about any pre-existing medical conditions or concurrent medications. | | 6 | Do not exceed the prescribed dosage. |
|
| additional informations | Individual response to strontium ranelate varies, and close monitoring is necessary. Efficacy in male osteoporosis is less clear than in post-menopausal osteoporosis. The doctor will be able to provide tailored advice based on the individual's specific situation. |
| patient profile | |
